Eledon Pharmaceuticals Inc. (ELDN)
ELDN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ELDN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001404281 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2016-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $6.9M cash; operating cash flow -$19.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 84,459,713 (2026-11-10); 59,932,212 a year earlier; 24,198,130 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-01 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Costa Mesa, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2025-04-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$3.9M | -$19.0M | $6.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$31.6M | -$22.7M | $6.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$39.0M | -$22.6M | $6.2M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$10.4M | -$14.1M | $22.8M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$17.5M | -$14.5M | $3.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$11.2M | -$17.7M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$6.5M | -$16.1M | $8.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$44.6M | -$19.0M | $20.5M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-05-01 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 617 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -18.8% |
| 1 month | -9.6% |
| 3 months | -42.8% |
| Year to date | +40.1% |
| 1 year | +20.2% |
| From 52-week high | -49.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| ADCT | ADC Therapeutics SA Common Shares | $1.25 | -6.72% | $159.7M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| BBOT | BridgeBio Oncology Therapeutics Inc. Common Stock | $1.98 | -7.48% | $158.9M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier